All In Biotech

Data reports

FDA-approved GLP-1 drugs list, and what Medicare spends on them

The FDA-approved GLP-1 drugs list with approval dates and companies, plus Medicare Part D GLP-1 spending from 2020 to 2024 and the semaglutide negotiation.

By the All In Biotech editorial team · Published November 18, 2026 · 5 min read

FDA has approved more than a dozen GLP-1-based products since 2005, from exenatide (Byetta) to the oral non-peptide orforglipron (Foundayo) in April 2026. In Medicare Part D, gross spending on Ozempic alone rose from $1.46 billion in 2020 to $12.97 billion in 2024, and semaglutide is one of the drugs with a Medicare negotiated price taking effect in 2027.

This post lists the approved products, shows Part D spending from 2020 to 2024 using CMS data, and explains the coverage rules that shape those numbers. It describes public data only and is not medical advice.

The approved GLP-1 drugs

GLP-1 receptor agonists mimic glucagon-like peptide-1, a gut hormone involved in insulin release, appetite and digestion. Tirzepatide also acts on the GIP receptor. The table lists the products in this site's Drugs@FDA catalog, as of November 2026.

BrandIngredientCompanyFirst approvedMain use
ByettaexenatideAstraZeneca2005-04-28Type 2 diabetes
VictozaliraglutideNovo Nordisk2010-01-25Type 2 diabetes
TrulicitydulaglutideEli Lilly2014-09-18Type 2 diabetes
SaxendaliraglutideNovo Nordisk2014-12-23Chronic weight management
Soliquainsulin glargine and lixisenatideSanofi2016-11-21Type 2 diabetes
Xultophyinsulin degludec and liraglutideNovo Nordisk2016-11-21Type 2 diabetes
Ozempicsemaglutide (injection)Novo Nordisk2017-12-05Type 2 diabetes
Rybelsussemaglutide (tablet)Novo Nordisk2019-09-20Type 2 diabetes
WegovysemaglutideNovo Nordisk2021-06-04Chronic weight management
Mounjarotirzepatide (GIP and GLP-1)Eli Lilly2022-05-13Type 2 diabetes
Zepboundtirzepatide (GIP and GLP-1)Eli Lilly2023-11-08Chronic weight management
Foundayoorforglipron (oral)Eli Lilly2026-04-01Chronic weight management

Notes on the table:

  • Ozempic has two NDAs in Drugs@FDA: NDA 209637 for the injection and NDA 213051, which also lists Rybelsus tablets.
  • Rybelsus was first approved on September 20, 2019 under NDA 213051. A separate Rybelsus NDA, 213182, was approved on January 16, 2020.
  • Wegovy has a second NDA, 218316, approved on December 22, 2025. See the original Wegovy page.
  • Labels change. Several of these drugs have gained further approved uses since first approval. Wegovy, for example, gained a cardiovascular risk reduction indication in March 2024. Check each label for current indications.
  • Discontinued products. Drugs@FDA also lists GLP-1 products marked discontinued, including extended-release exenatide (Bydureon and Bydureon BCise) and albiglutide (Tanzeum). Lixisenatide alone (Adlyxin, Sanofi) was approved in 2016.
  • Generics. Generic liraglutide has also been approved; ANDAs are not in this site's catalog.

Pages for Mounjaro and Zepbound show their approval histories, labels, safety reports and any recalls or shortages.

Medicare Part D spending on GLP-1 drugs, 2020 to 2024

The figures below come from CMS's Medicare Part D Spending by Drug data, as shown on this site in November 2026. They are gross spending in millions of dollars, before manufacturer rebates.

Drug20202021202220232024
Ozempic1,4562,6224,6289,19412,970
Mounjaronot on marketnot on market1442,3616,337
Trulicity3,2854,7026,2257,3645,454
Rybelsus734559751,6661,890

What the table shows:

  • Ozempic grew almost ninefold over five years, and its beneficiary count rose from 269,663 in 2020 to 1,952,637 in 2024. In 2024 it was the second-largest drug in Part D by gross spending, after Eliquis at $20.77 billion.
  • Mounjaro reached $6.34 billion in 2024, its third year in the data, with 894,581 beneficiaries.
  • Trulicity peaked in 2023 and fell in 2024.
  • Victoza 3-Pak fell from $1,546 million in 2020 to $203 million in 2024. Generic liraglutide appears in the 2024 data at $48 million.
  • Wegovy had $301 million in 2024 spending for 52,961 beneficiaries. Part D could cover it for cardiovascular risk reduction after the March 2024 label expansion.
  • Zepbound spending was negligible in the 2024 data.

For context, total gross Part D drug spending in these datasets was $194.1 billion in 2020 and $288.7 billion in 2024. Ozempic, Mounjaro, Trulicity and Rybelsus together accounted for about $26.7 billion of the 2024 total.

Why gross spending is not net cost

Part D spending figures are what plans and beneficiaries paid at the pharmacy, before rebates manufacturers pay back to plans. Rebates on diabetes drugs can be substantial, and they are confidential, so net spending is lower by an amount the public data does not show. For how to read these datasets, see how much Medicare spends on a drug.

Why weight-loss drugs show little Part D spending

The Medicare statute excludes drugs used for weight loss from Part D coverage. Part D can cover GLP-1 drugs for diabetes and for other medically accepted, FDA-approved uses. That explains much of the pattern in the table: the diabetes brands carry most of the spending, while Wegovy appears only after it gained a cardiovascular indication and Zepbound barely appears.

CMS explains Part D coverage rules on its prescription drug coverage page. Federal policy on Medicare coverage of obesity drugs has been the subject of recent proposals and announcements, and it changes often, so check cms.gov for the current position rather than relying on the rules as summarized here.

Semaglutide and Medicare price negotiation

Under the Inflation Reduction Act, CMS negotiates prices for selected high-spending drugs. In the second cycle, CMS selected 15 Part D drugs, and Ozempic, Rybelsus and Wegovy are listed together as one selected drug because they share the active ingredient semaglutide. CMS states that the negotiated prices, called maximum fair prices, take effect on January 1, 2027.

CMS's selected drugs and negotiated prices page lists all the selected drugs and links an explanation of each negotiated price. Because the 2024 data predates any negotiated price, the effect will only appear in later data years.

Safety reports

GLP-1 drugs also generate a large volume of adverse event reports. As of November 2026, openFDA's FAERS data had 70,721 reports naming Ozempic, with nausea, vomiting and diarrhoea among the most reported reactions. FAERS counts are reports, not confirmed cases, and do not show that a drug caused an event. For how to read them, see how to search FAERS, or look up a product on /faers.

FDA's page on medications containing semaglutide covers compounded and unapproved versions, which are not FDA-approved and are not in the table above.

How to keep this list current

New GLP-1-based drugs and label changes arrive regularly. To check the current position:

  1. Search /approvals for new novel approvals, or /conditions/obesity for products approved for weight management.
  2. Open each drug page for the latest label and supplement history.
  3. Check /pricing when CMS releases a new year of spending data.
  4. Check CMS's negotiation pages for the status of negotiated prices.

Questions about whether any of these drugs suits a particular person belong with a prescriber. The public data shows what FDA has approved, what Medicare has paid and what is changing.

Frequently asked questions

Which GLP-1 drugs are FDA approved?
Approved GLP-1 receptor agonists include exenatide (Byetta), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo), plus two insulin combinations.
How much does Medicare spend on Ozempic?
Medicare Part D gross spending on Ozempic was $12.97 billion in 2024, for 1,952,637 beneficiaries, before manufacturer rebates.
Does Medicare Part D cover GLP-1 drugs for weight loss?
By statute, Part D does not cover drugs used only for weight loss, but it can cover GLP-1 drugs for diabetes and other approved medical uses such as cardiovascular risk reduction.
Was semaglutide selected for Medicare price negotiation?
Yes. CMS selected Ozempic, Rybelsus and Wegovy, counted together as semaglutide, for the second negotiation cycle, with negotiated prices effective January 1, 2027.

For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.

Keep reading